Background and Purpose-The question whether cerebral microbleeds (CMBs) visible on MRI in acute stroke increase the risk for intracerebral hemorrhages (ICHs) or worse outcome after thrombolysis is unresolved. 
D espite continuous improvements of intravenous thrombolysis (IVT) and endovascular therapy (EVT) for acute ischemic stroke, 7% to 10.5% of the patients experience symptomatic intracerebral hemorrhage (sICH) that deteriorates their outcome. 1 Known risk factors for sICH are advanced age, higher baseline National Institutes of Health Stroke Scale (NIHSS) score, arterial hypertension, hyperglycemia, and signs of early infarct demarcation on computed tomography (CT) or MRI. 1 Whether preexisting cerebral microbleeds (CMB) increase the risk of ICH and whether thrombolytic therapy should even be withheld in these patients are controversial. Pathologists define CMB as small, mainly perivascular hemorrhages. On MRI, CMBs are visible as well-demarcated hypointense lesions. Hemoglobin degrades to the superparamagnetic hemosiderin that causes susceptibility artifacts and signal loss that is best seen on MRI sequences sensitive to magnetic susceptibility effects. 2, 3 CMB may contain intact erythrocytes in addition to hemosiderin and indicate recent bleeding that might increase the ICH risk of thrombolysis. A few studies addressed the potential risk of preexisting CMB on the post-thrombolysis bleeding risk and 2 recent metaanalyses came to contradicting conclusions. [4] [5] [6] [7] [8] [9] [10] Fiehler et al 4 considered the burden of CMB in their analysis, but to date no study addressed the question of the influence of location of CMB. The location might play a role because lobar predominance suggests cerebral amyloid angiopathy and deep white matter predominance hypertensive arteriopathy as likely pathogenesis. 2, 11, 12 Furthermore, most studies used T2*-gradient-echo-weighted magnetic resonance images that are less sensitive for CMB detection than the post processed susceptibility-weighted images (SWIs). 13, 14 The aim of this study was to analyze the impact of CMB burden and predominant location as detected on pretreatment SWI sequences on the post-thrombolysis bleeding risk in a large cohort of patients treated for acute ischemic stroke.
Methods

Patients and Treatment
The present study includes patients of the Bernese stroke registry, a prospectively collected database. Some of their aspects have been reported previously. [15] [16] [17] [18] Patients were included in this analysis if (1) diagnosis of ischemic stroke was established with a pretreatment MRI that included SWI sequences; (2) they underwent IVT, EVT, or IVT followed by EVT; and (3) a post-treatment MRI or CT scan was performed within 72 hours after acute therapy.
Age, sex, medication, NIHSS score, time from symptom onset to treatment, coronary artery disease, atrial fibrillation, arterial hypertension, diabetes mellitus, smoking, hypercholesterolemia, history of transient ischemic attack or ischemic stroke, family history of transient ischemic attack and stroke, treatment details (use of urokinase, mechanical procedures, bridging concept), and complications were recorded as baseline characteristics. The study was performed according to the ethical guidelines of the Canton of Bern and with approval of our institutional review board (Inselspital, University Hospital of Bern).
MRI Methods and Image Analysis
The standard stroke MRI protocol included diffusion-weighted imaging, T2-weighted imaging, time-of-flight magnetic resonance angiography, SWI, first-pass gadolinium-enhanced magnetic resonance angiography of the cervical and intracranial arteries, and perfusion imaging. The scans were acquired with a 1. The SWI and minimum intensity projection images were generated automatically by the scanner software.
Pretreatment Imaging Analysis
SWIs were analyzed for the presence of CMB in accordance with a previously published guideline. 3 A CMB was defined as a round or ovoid area of homogeneous signal loss on SWI with <5 mm in its largest diameter. To discern CMB from imaging mimics, the following criteria were applied: (1) the CMB had to exert a blooming effect, meaning that lesion size appeared larger on SWI than on spin echo sequences. (2) Signal drops of tubular or linear shape, most likely representing vascular structures or thrombus, as well as symmetrical hypointensities in the basal ganglia likely corresponding to calcifications or iron deposits, were not counted as CMB. (3) At least half of the lesion had to be surrounded by brain parenchyma. (4) If the hypointense SWI lesions were accompanied by a typical cavernous malformation or an adjacent developmental venous anomaly, they were not considered as CMB.
Anatomic localization of CMB was categorized according to the Microbleed Anatomic Rating Scale. 19 Subregions were lobar (frontal, parietal, temporal, occipital, and insula), deep (basal ganglia, thalamus, internal capsule, external capsule, corpus callosum, deep and periventricular white matter), or infratentorial (brain stem, cerebellum).
The most likely underlying vascular pathology was determined.
2,3,11
Categories of vascular pathology were hypertensive vasculopathy, cerebral amyloid angiopathy, and indeterminate. Hypertensive vasculopathy was assumed to be the most likely causative pathology if bleeds were located in deep white and gray matter, infratentorial regions or both. In addition, the patient had to be diagnosed with arterial hypertension. Cerebral amyloid angiopathy was assumed if the CMBs were located exclusively in lobar regions, the patient was ≥55 years, and no other cause of hemorrhage was present. 11 The existence of CMB, its burden, and location were scored by one author (P.P.G.) and checked by another (K.H.).
Post-Treatment Bleeding Complications
For follow-up imaging either an MRI or a noncontrast CT with CT angiography (Somatom Definition Edge; Siemens, Erlangen, Germany) was performed within 72 hours after treatment. Bleeding complications were graded according to the Prolyse in Acute Cerebral Thromboembolism (PROACT) II trial classification. 20 
Statistical Analysis
Data were analyzed using SPSS 21 (IBM Corp, Armonk, NY 
Stroke
June 2014
(lobar versus deep and infratentorial), and supposed pathogenesis of CMB were then each included in the final models to determine their impact. A P value of <0.05 was considered significant.
Results
From January 2010 to March 2013, we treated 724 patients with IVT, EVT, or IVT followed by EVT, of whom 392 patients had SWI images and fulfilled inclusion criteria. Baseline characteristics and treatment details are listed in Table 1 . IVT or bridging therapy was performed in 242 (61.7%) of the patients and EVT in 150 (38.3%) patients. In 259 (66.1%) patients pretreatment imaging was acquired with a 1.5-T and in 133 (33.9%) with a 3-T MRI system. CMBs were detected on pretreatment MRI in 79 (20.2%) patients. There was no significant difference in the detection rate of CMB at different MRI field strengths (1. 
Discussion
The main finding of this study is that the presence of CMB on pretreatment SWI sequences did not increase the risk for symptomatic or asymptomatic ICH or influence the outcome of 392 patients treated with IVT, EVT, or IVT followed by EVT. Only ICH outside the infarcted tissue was slightly more frequent in patients with preexisting CMB. Neither the predominant location of CMB nor their supposed pathogenesis was associated with bleeding complications or outcome. These results support the clinical practice that thrombolysis should not be withheld in patients with acute stroke and a high CMB burden.
At first glance the detection of CMB on MRI sequences sensitive to magnetic susceptibility effects may not indicate an elevated post-thrombolysis bleeding risk because CMBs are thought to be hemosiderin deposits of previous, old bleedings. 2, 3 Nevertheless, histopathologic findings of intact erythrocytes may also be a sign of recent bleeding in some CMB. 21 In addition, 2 studies found an increased risk for ICH in nonstroke patients with CMB, who were taking antiplatelet agents or oral anticoagulation. 22, 23 Only few studies addressed the potential risk of CMB and thrombolysis. [4] [5] [6] [7] [8] Two recent meta-analyses including the same studies of 790 IVT-treated patients concluded differently: Shoamanesh et al 10 found an increased risk for sICH in patients with CMB, whereas Charidimou et al 9 did not. Of the previous studies only 1 considered the burden of CMB 4 and none of the studies analyzed the location of CMB and the risk of ICH. In addition, none of the previous studies used SWIs, which are more sensitive for CMB detection than T2*-weighted images. 13, 14 We included 392 patients in our study. A total of 174 had been treated with IVT, 150 with EVT and 68 with IVT followed by EVT. There was ≥1 CMB on pretreatment SWI in 79 (20.2%) of our 392 patients, which is <34% as previously reported in patients with ischemic stroke. 12 This might be explained by a lower number of lacunar strokes or different risk factors in our thrombolysed patients compared with previous reports. We identified advancing age and arterial hypertension as risk factors for CMB. Other authors additionally found lacunar stroke, male sex, 24 diabetes mellitus, 12 and Asian ethnicity 12 to be risk factors for CMB. In subgroup analyses only in patients treated with IVT CMB were correlated positive with sICH (Table 3) , whereas in patients receiving EVT or IVT followed by EVT there was no correlation. The risk of sICH did not increase with the presence or burden of CMB. A high CMB burden was only associated with an increased risk of ICH outside the infarct (P=0.048) similar to a recent study, but the risk increase was only marginal (OR, 1.004). 25 There was no association of CMB with outcome and survival and no association of the predominant location and pathogenesis of CMB with bleeding or outcome. An autopsy study suggested a higher risk for ICH in patients with cerebral amyloid angiopathy, 11 but we did not find such an association in our patients.
The main limitation of our study is the retrospective analysis. In addition, we included patients treated with different thrombolysis techniques that might herald different risks for bleeding complications. Especially in the subgroup of 92 patients who received only mechanical thrombectomy, a lower bleeding risk can be expected, but consideration of treatment types in our subgroup analyses did not change the results. Nevertheless, we cannot rule out that our study is underpowered for the detection of a negative effect of preexisting CMB because of the low frequency of preexisting CMB, the low frequency of sICH, as well as a potential under-representation of specific groups of patients like those with extensive small vessel disease. Another potential limitation is the definition of CMB. We were using the definition suggested by Greenberg et al 3 and Cordonnier et al, 12 but there is no consensus definition of CMB. In conclusion, CMBs detected on pretreatment SWI were not associated with an increased risk for symptomatic or asymptomatic ICH or worse outcome in patients receiving thrombolysis. Consideration of CMB burden, predominant location, or presumed pathogenesis did not change this result. There was only a marginal risk increase for ICH outside the infarct that should not advise against thrombolysis in such patients.
